Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 68K | 28K | 20K | 36K | 15K |
| Gross Profit | -60K | -3K | -6K | 8K | 3K |
| Operating Income | 99K | -3M | -3M | -3M | -3M |
| EBITDA | -3M | 0 | 0 | 0 | 0 |
| Net Income | -3M | -3M | -3M | -2M | -3M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0629
-2.66% today
1Y Change
-44.70%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vivos Inc. (RDGL) is a Healthcare stock with a market cap of $30.00M and listed on OTC. The stock last traded around $0.06 and down 44.7% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of +144.3%, EPS growth of +4.2%, a dividend yield of 0.0%. What stands out right now is revenue +144.3%, EPS +4.2%, free cash flow -28.3% with operating margin -4629.4% and ROIC -178.3%. Valuation already assumes a fairly strong business story at price/sales 473.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RDGL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RDGL
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RDGL Max Drawdown
-61.96%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RDGL and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$14.9K
-59.2% YoY
FY Net Income
-$2.5M
-2.3% YoY
Free Cash Flow
-$963.8K
+13.9% YoY
Revenue Growth
+144.3%
EPS Growth
+4.2%
Gross Margin
-87.4%
Net Margin
-4483.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 68K | 28K | 20K | 36K | 15K |
| Gross Profit | -60K | -3K | -6K | 8K | 3K |
| Operating Income | 99K | -3M | -3M | -3M | -3M |
| EBITDA | -3M | 0 | 0 | 0 | 0 |
| Net Income | -3M | -3M | -3M | -2M | -3M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2M | 2M | 2M | 2M | 2M |
| Total Assets | 2M | 2M | 2M | 2M | 2M |
| Total Liabilities | 207K | 86K | 245K | 82K | 167K |
| Shareholder Equity | 2M | 2M | 1M | 2M | 1M |
| Total Debt | 114K | 0 | 0 | 0 | 0 |
| Net Debt | -1M | -2M | -2M | -2M | -2M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
964K
+13.9% YoY
Capital Expenditures
0
Free Cash Flow
964K
+13.9% YoY
Key ratios
Gross Margin
-87.4%
Operating Margin
-4629.4%
Net Margin
-4483.9%
ROE
-126.3%
Debt / Equity
0.07x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.